Adults with diabetes are 70% more likely to die from CVD than those without diabetes, according to the CDC.  But now we have a new drug that the FDA has approved for a new indication to prevent clinical cardiovascular disease. Empagliflozin (Jardiance) is now allowed to be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes (T2D) and cardiovascular disease (CVD). The agency based its decision on the results of a post-marketing study it required when it initially approved Jardiance in August 2014 as an adjunct to diet and exercise to improve glycemic control in adults with T2D. In a clinical trial of more than 7,000 patients with T2D and CVD, the use of Jardiance was found to reduce the risk of cardiovascular death compared with placebo when added to standard of care therapies for diabetes and atherosclerotic CVD. Additionally, Jardiance is not intended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. The drug is contraindicated in patients with a history of serious hypersensitivity reactions to Jardiance, severe renal impairment, end-stage renal disease, or dialysis. — FDA News Release Dec. 2016